



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

9632-005

APPLICATION NO.

09/328,296

APPLICANT

Siegall et al.

FILING DATE

06/08/99

GROUP

1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
KAC	AA	5,182,368	01/26/93	Ledbetter et al.	530	388.73	
	AB	5,674,492	10/07/97	Armitage et al.	424	144.1	
	AC	5,677,165	09/16/97	de Boer et al.	242	588.2	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
KAC	AD	WO 96/18413		PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	AE	Armitage et al., "Distinct patterns of inhibition by CD40 mAb of the CD40 ligand-CD40 interaction", in <u>Leukocyte Typing V</u> , Schlossman et al. (Eds.) 1995; 1: 551-552.
	AF	Bubenik J et al., "Monoclonal antibodies against human urinary bladder carcinomas: selectivity and utilization for gamma scintigraphy", <u>Eur J Cancer Clin Oncol.</u> 1985 Jun;21(6):701-10.
	AG	Challa A et al., "Epitope-dependent synergism and antagonism between CD40 antibodies and soluble CD40 ligand for the regulation of CD23 expression and IgE synthesis in human B cells", <u>Allergy.</u> 1999 Jun;54(6):576-83.
	AH	Clark EA and Ledbetter JA, "Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50", <u>Proc Natl Acad Sci U S A.</u> 1986 Jun;83(12):4494-8.
	AI	De Paoli P, "High CD40 membrane expression in AIDS-related lymphoma B cell lines is associated with the CD45RA+, CD45RO+, CD95+ phenotype and high levels of its soluble form in culture supernatants", <u>Cytometry.</u> 1997 Feb 15;30(1):33-8.
	AJ	Fanslow et al., "CD40 mAb M2 and M3 inhibit CD40 ligand binding and function", in <u>Leukocyte Typing V</u> , Schlossman et al. (Eds.) 1995; 1: 555-556.
	AK	Francisco JA et al., "Construction, expression, and characterization of BD1-G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin 1", <u>J Biol Chem.</u> 1997 Sep 26;272(39):24165-9.
	AL	Funakoshi S et al., "Inhibition of human B-cell lymphoma growth by CD40 stimulation", <u>Blood.</u> 1994 May 15;83(10):2787-94.
	AM	Funakoshi S et al., "Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas", <u>J Immunother Emphasis Tumor Immunol.</u> 1996 Mar;19(2):93-101.



AN	Gilliland LK et al., "Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments", <i>Tissue Antigens</i> . 1996 Jan;47(1):1-20.
AO	Grafton G et al., "Mechanisms of antigen receptor-dependent apoptosis of human B lymphoma cells probed with a panel of 27 monoclonal antibodies", <i>Cell Immunol</i> . 1997 Nov 25;182(1):45-56.
AP	Grewal IS and Flavell RA, "CD40 and CD154 in cell-mediated immunity", <i>Annu Rev Immunol</i> . 1998;16:111-35.
AQ	Herbert and Callard, "Inhibition of specific antibody production by CD40L and a panel of antibodies to CD40", in <i>Leukocyte Typing V</i> , Schlossman et al. (Eds.) 1995; 1:552-554.
AR	Katira et al., "CD40 Workshop Panel report", in <i>Leukocyte Typing V</i> , Schlossman et al. (Eds.) 1995; 1: 547-550.
AS	Katira et al., "Identification of co-operative epitopes on CD40 supports the existence of a second CD40 ligand", in <i>Leukocyte Typing V</i> , Schlossman et al. (Eds.) 1995; 1: 554.
AT	Kawabe et al., "Generation and characterization of CD40-deficient mice", in <i>Leukocyte Typing V</i> , Schlossman et al. (Eds.) 1995; 1: 550-551.
AU	Kehry MR. CD40-mediated signaling in B cells. Balancing cell survival, growth, and death", <i>J Immunol</i> . 1996 Apr 1;156(7):2345-8.
AV	Koho H et al., "Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder. I. Determination of the selectivity of six antibodies by cell ELISA and immunofluorescence", <i>Cancer Immunol Immunother</i> . 1984;17(3):165-72.
AW	Kuhne MR et al., "Assembly and regulation of the CD40 receptor complex in human B cells", <i>J Exp Med</i> . 1997 Jul 21;186(2):337-42.
AX	Malik N et al., "Activation of human monocytes through CD40 induces matrix metalloproteinases", <i>J Immunol</i> . 1996 May 15;156(10):3952-60.
AY	Murphy WJ et al., "Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes", <i>Blood</i> . 1995 Sep 1;86(5):1946-53.
AZ	Noelle RJ et al., "A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells", <i>Proc Natl Acad Sci U S A</i> . 1992 Jul 15;89(14):6550-4.
BA	Paulie S et al., "The human B lymphocyte and carcinoma antigen, CDw40, is a phosphoprotein involved in growth signal transduction", <i>J Immunol</i> . 1989 Jan 15;142(2):590-5.
BB	Pound JD et al, "Minimal cross-linking and epitope requirements for CD40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells", <i>Int Immunol</i> 1999 Jan;11(1):11-20.
BC	Speiser DE et al., "A regulatory role for TRAF1 in antigen-induced apoptosis of T cells", <i>J Exp Med</i> . 1997 May 19;185(10):1777-83.
BD	Stamenkovic I et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas", <i>EMBO J</i> . 1989 May;8(5):1403-10.
BE	Tutt AL et al., "Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors", <i>J Immunol</i> . 1998 Sep 15;161(6):3176-85.
BF	van Kooten C and Banchereau J, "Functions of CD40 on B cells, dendritic cells and other cells", <i>Curr Opin Immunol</i> . 1997 Jun;9(3):330-7.

KAC	BG	Yeh WC et al., "Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice", Immunity. 1997 Nov;7(5):715-25.
KAC	BH	Younes A et al., "Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia", Br J Haematol. 1998 Jan;100(1):135-41.
EXAMINER <i>Harmon A. Gamallo</i>		DATE CONSIDERED <i>5/14/2005</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

